GRAIL, Inc.
Metrics score locked — part of Premium
Price analysis
Chart shows the share price.
| Point in time | Price |
|---|---|
| Oct 31, 2025 | 79.6 EUR |
| Nov 7, 2025 | 68.7 EUR |
| Nov 14, 2025 | 68.4 EUR |
| Nov 21, 2025 | 81.2 EUR |
| Nov 28, 2025 | 95.4 EUR |
| Dec 5, 2025 | 86.7 EUR |
| Dec 12, 2025 | 77.4 EUR |
| Dec 19, 2025 | 77.8 EUR |
| Dec 26, 2025 | 77.7 EUR |
| Jan 2, 2026 | 75.8 EUR |
| Jan 9, 2026 | 86 EUR |
| Jan 16, 2026 | 83.2 EUR |
| Jan 23, 2026 | 89.3 EUR |
| Jan 30, 2026 | 82.1 EUR |
| Feb 6, 2026 | 84.8 EUR |
| Feb 13, 2026 | 82.2 EUR |
| Feb 20, 2026 | 42.7 EUR |
| Feb 27, 2026 | 45.1 EUR |
| Mar 6, 2026 | 43.4 EUR |
| Mar 13, 2026 | 37.5 EUR |
| Mar 20, 2026 | 40.5 EUR |
| Mar 27, 2026 | 42.1 EUR |
| Apr 3, 2026 | 47.7 EUR |
| Apr 10, 2026 | 39 EUR |
| Apr 17, 2026 | 43.8 EUR |
| Apr 24, 2026 | 46.5 EUR |
| May 1, 2026 | 46.2 EUR |
| May 8, 2026 | 52.4 EUR |
| May 15, 2026 | 51.3 EUR |
| May 22, 2026 | 57.9 EUR |
| May 29, 2026 | 61.6 EUR |
| Jun 5, 2026 | 51.5 EUR |
| Jun 12, 2026 | 51.7 EUR |
| Jun 19, 2026 | 55.6 EUR |
| Jun 26, 2026 | 57.8 EUR |
| Jul 3, 2026 | 60.4 EUR |
| Jul 10, 2026 | 63 EUR |
| Jul 17, 2026 | 63.5 EUR |
| Jul 24, 2026 | 59.6 EUR |
| Jul 31, 2026 | 59.7 EUR |
| Aug 7, 2026 | 60.2 EUR |
| Aug 14, 2026 | 58.7 EUR |
| Aug 21, 2026 | 68 EUR |
| Aug 28, 2026 | 68.7 EUR |
| Sep 4, 2026 | 69.1 EUR |
| Sep 11, 2026 | 65.8 EUR |
| Sep 18, 2026 | 70.5 EUR |
| Sep 25, 2026 | 111.3 EUR |
| Oct 2, 2026 | 127.6 EUR |
| Oct 9, 2026 | 125.5 EUR |
| Oct 16, 2026 | 104.7 EUR |
| Oct 23, 2026 | 118.4 EUR |
| Oct 26, 2026 | 125.1 EUR |
Price as of: Oct 26, 2026 closing price
Key metrics overview
Metrics score locked — part of Premium
Unlock metrics and scores View Premium
Valuation
- Price-to-Earnings Ratio
No meaningful value available - Price-to-Sales Ratio
Available with Premium - Price-to-Free-Cashflow
Available with Premium - Growth-Adjusted P/E
Available with Premium
Growth
Revenue Growth 38.37%- Earnings Growth
Available with Premium - Free Cash Flow Growth
Available with Premium - Net Margin Change
Available with Premium - Free Cash Flow Margin Change
Available with Premium - Earnings-per-Share Growth
Available with Premium - Growth Consistency
Available with Premium
Profitability
Return on Equity −16.12%- Return on Assets
Available with Premium - Return on Invested Capital
Available with Premium - Operating Profit Margin
Available with Premium - Net Profit Margin
Available with Premium
Stability
Revenue Stability 75 / 100- Earnings Stability
Available with Premium - Cashflow Stability
Available with Premium - Crisis Performance
Available with Premium - Price Fluctuations
Available with Premium - Maximum Price Loss
Available with Premium
Debt
- Debt-to-Equity Ratio
Available with Premium - Debt-to-Assets
Available with Premium - Net Debt / EBITDA
Available with Premium - Interest Coverage Ratio
Available with Premium
Cashflow
- Operating Cashflow
Available with Premium - Free Cashflow
Available with Premium - Free Cashflow Margin
Available with Premium
Dividends
- Dividend Yield
Available with Premium - Dividend Payout Ratio
Available with Premium - Dividend Growth
Available with Premium - Years without a cut
Available with Premium
Market comparison
The Fundamentals Score is higher than that of 40% of the other companies across the entire market and 43% of the other companies in the MedTech industry.
Revenue and Profit Performance
| Point in time | Revenue | Profit |
|---|---|---|
| FY25 (Dec 31, 2025) | 0.2 B USD | −0.4 B USD |
| FY24 (Dec 31, 2024) | 0.1 B USD | −2 B USD |
| FY23 (Dec 31, 2023) | 0.1 B USD | −1.5 B USD |
| FY22 (Jan 1, 2023) | 0.1 B USD | −5.4 B USD |
All amounts in billions USD
More Companies
The largest other companies in MedTech, part of the Healthcare sector.